Emerging evidence suggests glucagon-like peptide 1 receptor agonists (GLP-1RAs) might improve substance-use outcomes. University of Texas sought trials of GLP-1 receptor agonists for substance use disorders. It identified 33, with most trials focused on alcohol and nicotine, few trials for stimulant use disorders, and none for cannabis use disorder.


